(redirected from disease-specific mortality)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
References in periodicals archive ?
New research shows that few currently available screening tests for major diseases where death is a common outcome have documented reductions in disease-specific mortality. Evidence was evaluated on 16 screening tests for 9 major diseases where mortality is a common outcome.
"In conclusion, regardless of a higher risk of other-cause mortality and independent of tumour and treatment characteristics, disease-specific mortality increases with age among postmenopausal women with hormone receptor-positive breast cancer," the researchers said.
The effect of surgery on all-cause and disease-specific mortality did not vary by age, race, self-perceived health status, or the presence of comorbidities.
26.7%); and disease-specific mortality was lower for men diagnosed in the screening group (35% vs.
* BACKGROUND Cancer screening trials have traditionally focused on disease-specific mortality, the number of subjects whose death is attributed to the screened disease.
Disease-specific mortality was 35% for men diagnosed in the screening group and 45% for controls; overall mortality for men with prostate cancer was 81% in the screening group and 86% in controls.
Seven-year disease-specific mortality was 18% in the intermittent androgen suppression arm vs.
Consumption of whole grains, especially the bran component of whole grains, was associated with a significant decrease in the risk of all-cause mortality and cardiovascular disease-specific mortality in women with type 2 diabetes who were followed as part of the Nurses' Health Study.
Major Finding: Women with type 2 diabetes in the highest quintile of bran consumption had a 28% lower risk of all-cause mortality and 35% H lower risk of cardiovascular disease-specific mortality than women in the lowest quintile.
The new guidelines recommend that PET scans also may be used as part of initial staging in poorly differentiated thyroid cancers and invasive Hurthle cell carcinomas, as a prognostic tool in patients with metastatic disease to identify those patients at highest risk of rapid disease progression and disease-specific mortality, and as an evaluation of posttreatment response following systemic or local therapy of metastatic or locally invasive disease.